ClinicalTrials.gg
Active, not recruitingNCT05388669PALOMA-3Updated Nov 3, 2026Results posted

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 3 interventional study of Lazertinib and Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) in Advanced or Metastatic Non-small Cell Lung Cancer, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 187 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 3, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 15
418 · median 80
Started
2022
with 1 other
Phase 3
3 of 15
none open now
Primary completion
2024-01
later than 2 of 13 live
Registered
5th of 15
by date
Lead sponsor
8 of 15
Janssen Research & Development, LLC

Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About amivantamab

amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

03

Conditions studied

  • Advanced or Metastatic Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically confirmed, advanced or non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outside of the US)
  • Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease
  • Have at least 1 , according to (RECIST) version 1.1
  • Have an (ECOG) performance status of 0 to 1
  • Any toxicities from prior anticancer therapy must have resolved to (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to (\<=) 2 peripheral neuropathy, and Grade \<=2 hypothyroidism stable on hormone replacement)

Exclusion criteria

Exclusion Criteria:

  • Participant has received cytotoxic, , or targeted therapies beyond one regimen of platinum-based chemotherapy and EGFR inhibitors
  • Participant has received radiotherapy for palliative purposes less than 7 days prior to randomization
  • Participant has symptomatic or progressive
  • Participant has , or participant has spinal cord compression not definitively treated with surgery or radiation
  • Participant has uncontrolled tumor-related pain
  • Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Arm A: Lazertinib with Amivantamab SC-CF

    Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.

    Drug: Lazertinib · Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

  • Experimental
    Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion

    Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase.

    Drug: Lazertinib · Drug: Amivantamab Intravenous

Interventions

  • Lazertinib tablets will be administered orally.

    Also known as: JNJ-73841937, YH25448

  • DrugAmivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

    Drug page: Amivantamab

    Amivantamab injection will be administered subcutaneously by manual injection.

    Also known as: JNJ-61186372

  • Amivantamab will be administered by IV infusion.

    Also known as: JNJ-61186372

06

What researchers measure

Primary outcomes

  1. For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State

    Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration.

    Time frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)

  2. For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab

    Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration.

    Time frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)

  3. Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2

    AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported.

    Time frame: Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to 3 years 4 months

  2. Progression-Free Survival (PFS)

    Time frame: Up to 3 years 4 months

  3. Duration of Response (DOR)

    Time frame: Up to 3 years 4 months

  4. Time to Response (TTR)

    Time frame: Up to 3 years 4 months

  5. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 3 years 4 months

  6. Number of Participants With AEs by Severity

    Time frame: Up to 3 years 4 months

  7. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to 3 years 4 months

  8. Number of Participants With Clinical Laboratory Abnormalities by Severity

    Time frame: Up to 3 years 4 months

  9. Number of Participants With Infusion Related Reactions (IRRs)

    Time frame: Up to 3 years 4 months

  10. Number of Participants With IRRs by Severity

    Time frame: Up to 3 years 4 months

  11. For All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1

    Time frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)

  12. For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1

    Time frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)

  13. Model-Predicted Area Under the Concentration Time Curve of Amivantamab at Steady State From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 4

    Time frame: Cycle 4: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hrs post-dose on Day 1; Arm B: preinfusion, EOI+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1

  14. Percentage of Participants With Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies

    Time frame: Up to 3 years 4 months

  15. Percentage of Participants With Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ)

    Time frame: Up to 3 years 4 months

  16. Change From Baseline in Therapy Administration Satisfaction Questionnaire (TASQ) as Assessed Over Time

    Time frame: From baseline (Day 1, Cycle 1) to 3 years 4 months (each cycle of 28 days)

  17. Participant Chair Time

    Time frame: Up to 3 years 4 months

  18. Participant Chair Time in Treatment Room

    Time frame: Up to 3 years 4 months

  19. Duration of Treatment Administration

    Time frame: Up to 3 years 4 months

  20. Active Health Care Professional (HCP) Time For Drug Preparation, Treatment Administration and Post-treatment Monitoring

    Time frame: Up to 3 years 4 months

07

Results

Posted Feb 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
Started206212
Treated (safety analysis)206210
Completed4362
Not completed163150
Withdrew: Withdrawal by subject78
Withdrew: Lost to follow-up01
Withdrew: Other-ongoing156141

Outcome measures

PrimaryFor All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State

Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration.

Time frame:
Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
Reported as:
Geometric mean · micrograms per milliliters (mcg/mL)
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State
micrograms per milliliters (mcg/mL)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State206 ± 39.1144 ± 41.5
Statistical analysis
  • Arm A: Lazertinib With Amivantamab SC-CF vs Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion · Cox regression model: 1.427 · 90% CI 1.266 to 1.610
PrimaryFor EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab

Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration.

Time frame:
Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
Reported as:
Geometric mean · mcg/mL
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab
mcg/mLArm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab335 ± 32.7293 ± 31.7
Statistical analysis
  • Arm A: Lazertinib With Amivantamab SC-CF vs Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion · Cox regression model: 1.145 · 90% CI 1.040 to 1.261
PrimaryArea Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2

AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported.

Time frame:
Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
Reported as:
Geometric mean · micrograms*hour per milliliters
Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2
micrograms*hour per millilitersArm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2135861 ± 30.7131704 ± 24.0
Statistical analysis
  • Arm A: Lazertinib With Amivantamab SC-CF vs Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion · Geometric mean ratio: 1.032 · 90% CI 0.976 to 1.090
SecondaryObjective Response Rate (ORR)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With AEs by Severity
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Abnormalities
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Abnormalities by Severity
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Infusion Related Reactions (IRRs)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With IRRs by Severity
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryFor All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1
Time frame:
Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryFor EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1
Time frame:
Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryModel-Predicted Area Under the Concentration Time Curve of Amivantamab at Steady State From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 4
Time frame:
Cycle 4: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hrs post-dose on Day 1; Arm B: preinfusion, EOI+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ)
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Therapy Administration Satisfaction Questionnaire (TASQ) as Assessed Over Time
Time frame:
From baseline (Day 1, Cycle 1) to 3 years 4 months (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryParticipant Chair Time
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryParticipant Chair Time in Treatment Room
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryDuration of Treatment Administration
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

SecondaryActive Health Care Professional (HCP) Time For Drug Preparation, Treatment Administration and Post-treatment Monitoring
Time frame:
Up to 3 years 4 months

Results for this outcome have not been posted.

Adverse events

Collected over All cause mortality: From baseline (Day 1) up to 17 months; SAEs and other AEs: From baseline (Day 1) up to 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Lazertinib With Amivantamab SC-CF43/206 (20.9%)59/206 (28.6%)201/206 (97.6%)
Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion61/210 (29%)64/210 (30.5%)207/210 (98.6%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventArm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
PneumonitisRespiratory, thoracic and mediastinal disorders9/2066/210
PneumoniaInfections and infestations3/2067/210
Covid-19Infections and infestations4/2064/210
Alanine Aminotransferase IncreasedInvestigations4/2063/210
Deep Vein ThrombosisVascular disorders2/2064/210
FatigueGeneral disorders3/2061/210
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders3/2061/210
NauseaGastrointestinal disorders0/2063/210
Cerebral InfarctionNervous system disorders0/2063/210
VomitingGastrointestinal disorders2/2060/210
Most frequent other events
Showing 10 of 58
Most frequent other events
EventArm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) Infusion
Infusion Related ReactionInjury, poisoning and procedural complications27/206137/210
ParonychiaInfections and infestations111/206108/210
HypoalbuminaemiaMetabolism and nutrition disorders96/20676/210
RashSkin and subcutaneous tissue disorders95/20691/210
StomatitisGastrointestinal disorders57/20669/210
Dermatitis AcneiformSkin and subcutaneous tissue disorders64/20669/210
NauseaGastrointestinal disorders60/20652/210
Oedema PeripheralGeneral disorders52/20658/210
Alanine Aminotransferase IncreasedInvestigations46/20654/210
Decreased AppetiteMetabolism and nutrition disorders45/20652/210

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) InfusionTotal
Mean60.8 ± 9.7661.4 ± 10.7161.1 ± 10.25
Age, Customized
Age, Customized(Participants)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) InfusionTotal
<50 years282957
50-64 years10591196
65-74 years5570125
>=75 years182240
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) InfusionTotal
Female138141279
Male6871139
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) InfusionTotal
American Indian or Alaska Native000
Asian126129255
Native Hawaiian or Other Pacific Islander000
Black or African American134
White7877155
More than one race011
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(Participants)Arm A: Lazertinib With Amivantamab SC-CFArm B: Lazertinib With Amivantamab Intravenous (IV) InfusionTotal
Argentina5611
Australia12517
Brazil61117
Canada71118
China464793
France347
Germany235
Israel9413
Italy131427
Japan263056
Malaysia8917
Poland303
Portugal325
Korea, South212041
Spain141529
Taiwan6612
Thailand527
Turkey527
United Kingdom022
United States121931
08

Study locations

187 sites

Showing the first 100 of 187 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Leighl NB, Passaro A, Akamatsu H, Spira AI, Nguyen D, Qin A, Schuchard J, Gamil M, Baig M, Alexander M. Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer. Future Oncol. 2026 Aug 24:1-17. doi: 10.1080/14796694.2026.2709936. Online ahead of print. PubMed 42635093 ↗
  • Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massuti B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Sendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10. PubMed 38857463 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2024, 16 months.

Results were first posted in Feb 2026, 2 years after primary completion. A results delay was requested in Dec 2024.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 16 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 24, 2022
StartActual
Aug 5, 2022
Primary completionActual
Jan 3, 2024
CompletionEst.
Jun 30, 2027
Results delay requested
Dec 20, 2024
Results first posted
Feb 2, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 Argentina, 1 Israel)
  • Centro Oncológico Korben · Chabas, Argentina
  • Shaare Zedek Medical Center · Yeruham, Israel
Show 2 removed
  • Centro Oncológico Korben · Buenos Aires, Argentina
  • Shaare Zedek Medical Center · Jerusalem, Israel
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Argentina, 1 Israel)
    • Centro Oncológico Korben · Chabas, Argentina
    • Shaare Zedek Medical Center · Yeruham, Israel
    Show 2 removed
    • Centro Oncológico Korben · Buenos Aires, Argentina
    • Shaare Zedek Medical Center · Jerusalem, Israel
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05388669
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Aug 5, 2022
Primary completion
Jan 3, 2024
Completion
Jun 30, 2027 (estimated)
Results posted
Feb 2, 2026
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amivantamab

Start the discussion